SAB Biotherapeutics Inc
NASDAQ:SABS
Relative Value
The Relative Value of one SABS stock under the Base Case scenario is hidden USD. Compared to the current market price of 3.63 USD, SAB Biotherapeutics Inc is hidden .
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
SABS Competitors Multiples
SAB Biotherapeutics Inc Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
US |
S
|
SAB Biotherapeutics Inc
NASDAQ:SABS
|
33.5m USD | 15 | -0.8 | 0.6 | 0.5 | |
US |
Abbvie Inc
NYSE:ABBV
|
293.9B USD | 5.4 | 49.4 | 13.8 | 21.3 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
167.6B USD | 5.7 | 44.5 | 18.7 | 30.9 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
115B USD | 11.3 | 28.6 | 24 | 25.1 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
108.2B USD | 8.3 | 28.1 | 22.7 | 25.2 | ||
AU |
CSL Ltd
ASX:CSL
|
135.3B AUD | 6.4 | 36.6 | 22.1 | 27.4 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
84.4B USD | 3.1 | 174.3 | 8.8 | 11.6 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
50.9B USD | 9.9 | -8.5 | -9.4 | -8.4 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
33.6B USD | 3.5 | 28.8 | 14.6 | 18.3 | ||
KR |
Celltrion Inc
KRX:068270
|
39.7T KRW | 18.2 | 74.1 | 45.3 | 62.4 |